Revolution Medicines, Inc. Stock Price, News & Analysis

Revolution Medicines, a clinical-stage oncology company, reported its Q1 2022 financial results, revealing a net loss of $57.6 million, up from $37.2 million in Q1 2021. Total revenue decreased to $7.6 million from $10.2 million year-over-year, mainly due to lower reimbursed development costs with Sanofi. However, the company is advancing its RAS(ON) Inhibitor pipeline, with RMC-6236 and RMC-6291 set to enter clinical trials this year. The company maintains a strong cash position of $518.8 million and expects a full-year net loss of $260 million to $290 million for 2022.

Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the upcoming release of its financial results for Q1 2022 on May 9, 2022, after market close. The senior management team will conduct a conference call and webcast at 4:30 PM ET to discuss these results and update investors on corporate progress. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, including a diverse pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors. More details on the call can be found on their investor relations website.

Revolution Medicines (Nasdaq: RVMD) will present its pipeline of RAS(ON) Inhibitors at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The company plans to deliver seven oral presentations, focusing on novel therapies targeting RAS-addicted cancers. Key presentations include insights into RMC-6236, RMC-6291, RMC-9805, and RMC-8839. The company’s innovative tri-complex platform showcases potential first-in-class treatments capable of addressing significant patient needs. Collaborators will also present findings on related therapies.

Revolution Medicines, a clinical-stage oncology company focused on RAS-addicted cancers, announces participation in the Cowen 42nd Annual Health Care Conference. CEO Mark A. Goldsmith will engage in a fireside chat on March 7, 2022, at 11:10 a.m. Pacific. The virtual conference runs from March 7-9, 2022, with a live webcast available on the company’s website. A replay will be accessible for 14 days post-event. Revolution Medicines develops therapies targeting RAS proteins, including RMC-6236 and RMC-4630.

Revolution Medicines (Nasdaq: RVMD) reported financial results for Q4 and full year 2021, with total revenue of $29.4 million, a decline from $43.0 million in 2020. The net loss increased to $187.1 million in 2021 from $108.2 million. The company is advancing its RAS(ON) Inhibitor pipeline, with drug candidates RMC-6236 and RMC-6291 expected to enter clinical trials. New drug candidates RMC-9805 and RMC-8839 have also been nominated. Revolution Medicines anticipates a GAAP net loss of $260 million to $290 million for 2022, including stock-based compensation expenses.

Revolution Medicines, a clinical-stage oncology company, will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and webcast are scheduled for the same day at 4:30 p.m. Eastern Time to discuss the results and recent corporate developments. Investors can access the live webcast and archived version on the company’s website. Revolution Medicines focuses on developing novel targeted therapies for RAS-addicted cancers, including a range of RAS(ON) Inhibitors and Companion Inhibitors.

Revolution Medicines (Nasdaq: RVMD), focusing on targeted therapies for RAS-addicted cancers, will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. CEO Mark A. Goldsmith will lead a fireside chat, scheduled for 12:30 p.m. Pacific on February 10, 2022, during the virtual event from February 9-11, 2022. Interested parties can access the live webcast and a subsequent replay on the company's Events & Presentations page. Revolution Medicines is advancing its R&D pipeline with various RAS(ON) inhibitors and RAS Companion Inhibitors.

Revolution Medicines (RVMD) reported significant advancements in its RAS(ON) Inhibitor pipeline during the J.P. Morgan Healthcare Conference. The company has dosed the first patient in a Phase 2 trial combining RMC-4630 with Lumakras™ for advanced non-small cell lung cancer. Two new drug candidates, RMC-9805 and RMC-8839, are set for IND filings in 2023. Initial results for RMC-5552 indicate encouraging activity in treating advanced tumors. Overall, the updates reflect strong momentum in addressing unmet medical needs for RAS-addicted cancers.

Revolution Medicines (RVMD) announced that CEO Mark A. Goldsmith will present at the 40th Annual J.P. Morgan Healthcare Conference from January 10-13, 2022. The presentation, scheduled for January 11 at 2:15 p.m. ET, will focus on the expansion of the company’s RAS(ON) Inhibitors pipeline, specifically RMC-6236 and RMC-6291, alongside updates on clinical-stage RAS Companion Inhibitors RMC-4630 and RMC-5552. Investors can access the live webcast through the company’s website and a replay will be available for 14 days post-conference.